key: cord-0806114-7fjdsekn authors: Cismaru, Cosmin Andrei; Cismaru, Gabriel Laurentiu; Nabavi, Seyed Fazel; Ghanei, Mostafa; Burz, Claudia Cristina; Nabavi, Seyed Mohammad; Berindan Neagoe, Ioana title: Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID‐19 date: 2020-11-19 journal: J Cell Mol Med DOI: 10.1111/jcmm.15927 sha: d62573f9b5f5d269fac2f892cd069c4a6d4862e2 doc_id: 806114 cord_uid: 7fjdsekn COVID‐19 can present with a variety of clinical features, ranging from asymptomatic or mild respiratory symptoms to fulminant acute respiratory distress syndrome (ARDS) depending on the host's immune responses and the extent of the associated pathologies. This implies that several measures need to be taken to limit severely impairing symptoms caused by viral‐induced pathology in vital organs. Opioids are most exploited for their analgesic effects but their usage in the palliation of dyspnoea, immunomodulation and lysosomotropism may represent potential usages of opioids in COVID‐19. Here, we describe the mechanisms involved in each of these potential usages, highlighting the benefits of using opioids in the treatment of ARDS from SARS‐CoV‐2 infection. analgesic and psychoactive properties. It is most abundant in opium poppy (Papaver somniferum L) 4 and acts directly on the central nervous system (CNS) to alleviate pain. By its chemical structure, morphine derives from a hydride of a morphinan, being a conjugate base of a morphine (1+). Specific opiate receptors for morphine are found in brain and control different functions, including analgesia, euphoria, sedation, anxiolysis and respiratory depression. 5 The opioid receptors have been previously described and are represented by miu(µ), delta(δ) and kappa(κ) receptors. While many of them are involved in the perception of pain and dyspnoea, opioid receptors are also found in the digestive system inhibiting bowel movement and on the surface of immune cells having immunomodulatory effects. 6 Opioids are widely used for treating moderate to severe pain in patients who require potent analgesia, mostly in the setting of acute trauma, childbirth, invasive procedures and chronic end-stage illnesses. 7 While strong opioids are potent analgesics, less strong representatives such as codeine and DHC have more pronounced effects on cough, 8 diarrhoea 9 and dyspnoea. 10 Opiate drugs have long been known to exert effects on the respiratory system. These include reducing the respiratory response to CO 2 , 11 hypoxia, 12 inspiratory flow-resistive loading 13 and exercise, 14 with overdoses being capable of producing respiratory depression. 15 Opioid receptors from various areas of the CNS and the cardio-respiratory systems seem responsible for the mediation of the mechanisms of their antidyspnoeic effects. [16] [17] [18] Moreover, in the palliation of dyspnoea, opioids are the only agents with sufficient pharmacological evidence. 10, 19, 20 These are some of the arguments which led to the usage of opioids in the palliation of dyspnoea, being recommended by European and US therapeutic guidelines. 21, 22 Treatment of dyspnoea outside oncological pathology such as the chronic obstructive pulmonary diseases (COPD) [23] [24] [25] is emerging as an indication in professional society guidelines such as the GOLD. 26 While special precautions regarding morphine usage in patients with severe renal insufficiency, the dosage and dosage intervals require adaptation to the renal function for all µ-opioids due to their renal elimination. [27] [28] [29] In patients without severely impaired kidney function, they can be used in both opioid-naïve and opioid-treated patients without relevant breath depression, impaired oxygenation or increase in CO2 concentration. 30 While dyspnoea and anxiety occur most often as associated events, opioids have been known to reduce the subjective perception of breathlessness, mainly by increasing the amplitude of breaths and limiting hyperventilation and tachypnoea while exerting anxiolytic effects. No opioid is superior to another in treating dyspnoea and oxycodone, and hydromorphone and fentanyl can be used for this purpose, while dihydrocodeine, diamorphine, oral and paranteral morphine have the most evidence for this use. 23, [31] [32] [33] Opioid-naïve patients require smaller doses of opioids for dyspnoea than for the palliation of pain. However, patients already on opioid treatment will require increases of the baseline dosage of up to 25%-50% for the palliation of dyspnoea. 34 This is associated with the advantages of significant decrease in the intensity of dyspnoea, tachypnoea and no higher risk of respiratory depression but with the drawback of unwanted side-effects such as initial nausea and constipation. 35 as much of its pathology is associated with the dysregulation of the renin-angiotensin system (RAS) from antagonization of angiotensinconverting enzyme 2 (ACE2). 40 Besides, activation of the inflammasome with subsequent adaptative immune responses and cytokine release syndrome or the cytokine storm is seen in SARS-CoV 41 as well as in SARS-CoV-2 pathogenesis. 42 While a reduced pathogenesis from cytokine release and inflammatory cell infiltration in the lungs has been observed with the immunomodulatory effect of opioids in various viral infections, immunosuppression from extended use is not to be overlooked. 43, 44 In COVID-19, the distribution of ACE2 receptors mostly in lung tissue but also in heart, kidney, brain and endothelia makes the respiratory tract carry the most important load of viral-induced pathology and the other organs expressing ACE2 the second most affected by the viral replication and the hosts' response against it. Most of the pathology is induced by the immune response against the invading pathogen rather than the infection itself as the virus uses the replicative machinery of the cell followed by budding for its egress rather than cell lysis. 45 The host cell death can occur if excess Ang II is produced leading to direct apoptosis 46 and when excess protein is produced with endoplasmic reticulum (ER) stress, unfolded protein response (UPR) and subsequent apoptosis. 47 The authors declare no competing interests. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS Air hunger and psychological trauma in ventilated patients with COVID-19. An urgent problem Inheritance pattern and conservative genetics study tool: descriptors on opium poppy (Papaver somniferum L.) Untangling the complexity of opioid receptor function Evidence for opioid receptors on cells involved in host defense and the immune system Morphine: uses, dosage, side effects, warnings -Drugs Assessment and Management of Chronic Cough. Assessment and Management of Chronic Cough Role of codeine in palliative care Opioids, exertion, and dyspnea: a review of the evidence The effects of narcotics upon the respiratory response to carbon dioxide in man Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man Effect of meperidine on occlusion pressure responses to hypercapnia and hypoxia with and without external inspiratory resistance Effects of morphine on ventilatory response to exercise Nonanalgesic effects of opioids: opioid-induced respiratory depression The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala Opioids depress cortical centers responsible for the volitional control of respiration Dyspnea and pain share emotion-related brain network Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study Treatment of dyspnoea in advanced cancer patients: ESMO clinical practice guidelines Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version Panel Members Palliative Care 1 Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases Palliation of dyspnoea in advanced COPD: revisiting a role for opioids Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists Global initiative for chronic obstructive lung disease global initiative for chronic obstructive lung disease pocket guide to COPD diagnosis, management, and prevention: a Guide for Health Care Professionals A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC Fentanyl for the relief of refractory breathlessness: a systematic review Intravenous fentanyl for dyspnea at the end of life: lessons for future research in dyspnea Effect of hydromorphone on ventilation in palliative care patients with dyspnea How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial Is there a higher risk of respiratory depression in opioid-nave palliative care patients during symptomatic therapy of dyspnea with strong opioids? Opioids, opioid receptors, and the immune response Immunomodulatory effect of morphine: therapeutic implications Immunologic effects of opioids in the presence or absence of pain Advances in antifibrotic therapy Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 -can we end this viral series Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19) opioid receptors control viral replication in the airways Opioids and viral infections: a double-edged sword Virus maturation by budding RhACE2 -playing an important role in inhibiting apoptosis induced by Ang II in HUVECs Mediators of endoplasmic reticulum stress-induced apoptosis Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China Neurological manifestations of COVID-19: a review of what we know so far Neurological manifestations of COVID-19: a review Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents Lysosomotropic agents How an animal virus gets into and out of its host cell Uptake and intracellular localization of morphine in lysosomes and cell sap of cultured fibroblasts HIV-1 and morphine regulation of autophagy in microglia: limited interactions in the context of HIV-1 infection and opioid abuse Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Coronavirusesdrug discovery and therapeutic options Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19